Prudential Financial
BCAX

Prudential Financial’s Bicara Therapeutics BCAX Stock Holding History

Prudential Financial’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Sell
7,170
-20,160
-74% -$450K ﹤0.01% 2209
2026
Q1 		$544K Buy
+27,330
New +$470K ﹤0.01% 1831

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prudential Financial's BCAX Position: Q2 2026 in Review

Prudential Financial reduced its Bicara Therapeutics (BCAX) stake by 74% in Q2 2026, selling an estimated $450K and leaving 7,170 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #2209.

Prudential Financial first reported a position in BCAX in Q1 2026 and has held it in 2 quarters since. The position peaked at $544K in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Prudential Financial held 7,170 shares of Bicara Therapeutics worth $213K as of Q2 2026.
  • Prudential Financial sold 20,160 Bicara Therapeutics shares in Q2 2026, an estimated $450K.
  • Bicara Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #2209 holding.
  • Prudential Financial first reported a position in Bicara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Prudential Financial's Bicara Therapeutics position peaked at $544K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.